Results 81 to 90 of about 46,843 (269)

Effects of Combined Treatment With Arsenic Trioxide and Itraconazole in Patients With Refractory Metastatic Basal Cell Carcinoma.

JAMA dermatology, 2016
IMPORTANCE Tumor resistance is an emerging problem for Smoothened (SMO) inhibitor-treated metastatic basal cell carcinoma (BCC). Arsenic trioxide and itraconazole antagonize the hedgehog (HH) pathway at sites distinct from those treated by SMO inhibitors.
M. Ally, K. Ransohoff, K. Sarin, Scott X. Atwood, Melika Rezaee, I. Bailey-Healy, Jynho Kim, P. Beachy, Anne Lynn S. Chang, A. Oro, Jean Y. Tang, A. Dimitrios Colevas   +11 more
semanticscholar   +1 more source

Physiologically Based Pharmacokinetic Model of Itraconazole and Two of Its Metabolites to Improve the Predictions and the Mechanistic Understanding of CYP3A4 Drug-Drug Interactions

Drug Metabolism And Disposition, 2018
Physiologically based pharmacokinetic (PBPK) modeling for itraconazole using a bottom-up approach is challenging, not only due to complex saturable pharmacokinetics (PK) and the presence of three metabolites exhibiting CYP3A4 inhibition, but also because
Luna Prieto Garcia, D. Janzén, Kajsa P. Kanebratt, H. Ericsson, H. Lennernäs, A. Lundahl   +5 more
semanticscholar   +1 more source

Trichophyton mentagrophytes type VII: cohort study on patient characteristics, clinical features, disease course, and treatment

JDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary Background and Objectives Sexually transmitted infections with Trichophyton mentagrophytes type VII (TMVII) have been reported in several countries. The aim of our study was to identify epidemiological and clinical features in order to improve prevention, diagnosis, and treatment.
Konstanze Kämmerer, Julia Huynh, Cornelia Deutsch, Stefanie May, Sertac Uyar, Alexander Nast, Christoph Zeyen, Ricardo Niklas Werner   +7 more
wiley   +1 more source

An Unusual Case Report of Iatrogenic Metrorrhagia and Hematochezia Following Itraconazole

Clinical Dermatology Review
Itraconazole is an effective triazole antimycotic drug that has a desirable pharmacokinetic profile to combat various fungal pathogens. It acts by inhibiting ergosterol biosynthesis in fungal cell membranes.
Yashaswi Rai
doaj   +1 more source

Disseminated Cutaneous Blastomycosis

JEADV Clinical Practice, EarlyView.
Lorena Alexandra Mija, Elio Kechichian, Carolina Lucena Fernandes   +2 more
wiley   +1 more source

Trichophyton indotineae: Epidemiology, antifungal resistance and antifungal stewardship strategies

Journal of the European Academy of Dermatology and Venereology, EarlyView.
There is a concerning trend of widespread and severe superficial fungal infections caused by a new pathogen—Trichophyton indotineae—resistant to standard antifungal therapies. T. indotineae is now spreading globally and evolving. There is increasing urgency for healthcare providers and policy makers to initiate surveillance systems and antifungal ...
Aditya K. Gupta, Susmita, Hien C. Nguyen, Amanda Liddy, Mesbah Talukder, Tong Wang, Lee Magal, Anuradha Chowdhary, Avner Shemer, Ditte Marie L. Saunte, Roderick Hay, Vincent Piguet   +11 more
wiley   +1 more source

Formulation and Characterization of Itraconazole as Nanosuspension Dosage Form for Enhancement of Solubility

Iraqi Journal of Pharmaceutical Sciences, 2019
Itraconazole is a triazole antifungal given orally for the treatment of oropharyngeal and vulvovaginal candidiasis, for systemic infections including aspergillosis, candidiasis,  and for the prophylaxis of fungal infections in immunocompromised patients.
Asmaa M. Rashid, Shaimaa N. Abdal-Hammid
doaj   +1 more source

Treatment outcomes in sinonasal aspergillosis in dogs in the United Kingdom: 436 cases (2011‐2021)

Journal of Small Animal Practice, EarlyView.
Objectives A variety of treatment options for sinonasal aspergillosis have been described, encompassing non‐invasive and invasive approaches. To describe the clinical outcomes in dogs treated for sinonasal aspergillosis in the United Kingdom. Materials and Methods A multi‐centre retrospective survey was performed involving 23 referral centres in the ...
C. D. Prior, H. Swales, A. Kortum, N. Reed, M. Sharman, D. Kelly, A. Kent, B. Glanemann, K. Clarke, C. Lea, E. Roberts, N. Bommer, L. Rutherford, A. Tamborini, K. Murphy, D. J. Batchelor, S. Calleja, R. Burrow, P. M. Jamieson, C. Piazza, M. Best, I. Calvo Saiz, I. Elgueta, S. J. Fowlie, C. Shales, C. Gil Morales, E. Lopez, S. Borgonovi, M. Keane, J. Kennils, E. Izaguirre, M. Hernandez‐Perello, N. Lau, A. Paul, A. Ridyard, E. Shelton, A. Farges, G. Specchia, L. Espada, S. Spence, A. Hrovat, N. Van den Steen, S. Tappin, T. H. Sparks, F. Allerton   +44 more
wiley   +1 more source

Repurposing itraconazole for the treatment of cancer.

Oncology Letters, 2017
The repurposing of drugs is becoming increasingly attractive as it avoids the lengthy process and cost implications associated with bringing a novel drug to market. Itraconazole is a broad-spectrum anti-fungal agent. An emerging body of in vivo, in vitro
R. Pounds, Sarah M. Leonard, C. Dawson, S. Kehoe   +3 more
semanticscholar   +1 more source

Presumed Trichophyton indotineae Infection in Children: A Call for Heightened Clinical Awareness

Pediatric Dermatology, EarlyView.
ABSTRACT Trichophyton indotineae is a fungus that is often antifungal‐resistant and presents with exuberant infection. It has been increasingly reported across the world, posing significant diagnostic challenges. We describe a case of a toddler with a history of travel to Bangladesh, presenting with persistent annular scaling plaques of dermatophytosis
Sriram Palepu, James R. Treat
wiley   +1 more source